Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team (2014) Ann Intern Med 161: 461-71 The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) J Clin Invest 101: 289-94 Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF (2001) Proc Natl Acad Sci U S A 98: 13288-93 Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clough LA, D'Agata E, Raffanti S, Haas DW (1999) Clin Infect Dis 29: 75-81; discussion 82-4 Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Haas DW (2006) Clin Infect Dis 42: 1197-9 Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Haas DW, Stone J, Clough LA, Johnson B, Spearman P, Harris VL, Nicotera J, Johnson RH, Raffanti S, Zhong L, Bergqwist P, Chamberlin S, Hoagland V, Ju WD (2000) Clin Pharmacol Ther 68: 367-74 Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW (2003) Clin Pharmacol Ther 73: 78-86 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC) (2013) AIDS 27: 803-13 Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas DW, Haubrich R, Stanford J, Horton J, Landay A, Spreen W (2000) AIDS 14: 2635-42 The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, Fiedorek FT, Haas DW (2004) AIDS 18: 2137-44 European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA (2011) AIDS 25: 37-47 Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV, AIDS Clinical Trials Group (ACTG) A5142 Study Team (2009) AIDS 23: 1109-18 Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. Saah AJ, Haas DW, DiNubile MJ, Chen J, Holder DJ, Rhodes RR, Shivaprakash M, Bakshi KK, Danovich RM, Graham DJ, Condra JH (2003) J Infect Dis 187: 1157-62 Pharmacogenomics and HIV therapeutics. Haas DW (2005) J Infect Dis 191: 1397-400 Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. Forshey BM, Shi J, Aiken C (2005) J Virol 79: 869-75 Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W (2005) J Acquir Immune Defic Syndr 38: 277-82 Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, Alston-Smith B, Acosta EP, A5213 StudyTeam (2009) J Acquir Immune Defic Syndr 50: 290-3 MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB (2003) J Acquir Immune Defic Syndr 34: 295-8 Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Haas DW, Johnson B, Nicotera J, Bailey VL, Harris VL, Bowles FB, Raffanti S, Schranz J, Finn TS, Saah AJ, Stone J (2003) Antimicrob Agents Chemother 47: 2131-7 Towards ligand docking including explicit interface water molecules. Lemmon G, Meiler J (2013) PLoS One 8: e67536 Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW (2014) Pharmacogenet Genomics 24: 195-203 Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Hosea NA, Miller GP, Guengerich FP (2000) Biochemistry 39: 5929-39 Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Drug Metab Dispos 28: 655-60 Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Hileman CO, Longenecker CT, Carman TL, Milne GL, Labbato DE, Storer NJ, White CA, McComsey GA (2012) Antivir Ther 17: 1345-9 Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. McMahon D, Lederman M, Haas DW, Haubrich R, Stanford J, Cooney E, Horton J, Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellors JW (2001) Antivir Ther 6: 105-14 NMR structure-based drug design. Fesik SW (1993) J Biomol NMR 3: 261-9 Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH (2013) Cancer Chemother Pharmacol 71: 1567-76 Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, Fletcher CV, Fiscus S, Raffanti S, Donlon R, McKinsey J, Nicotera J, Schmidt D, Shoup RE, Kates RE, Lloyd RM, Larder B (2000) AIDS Res Hum Retroviruses 16: 1491-502 Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand. Lemmon G, Kaufmann K, Meiler J (2012) Chem Biol Drug Des 79: 888-96 Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T (2009) HIV Clin Trials 10: 181-92 Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Zhang X, Tierney C, Albrecht M, Demeter LM, Morse G, DiFrancesco R, Dykes C, Jiang H, Haas DW (2013) Ther Drug Monit 35: 209-16 Measures of small-fiber neuropathy in HIV infection. Boger MS, Hulgan T, Haas DW, Mitchell V, Smith AG, Singleton JR, Peltier AC (2012) Auton Neurosci 169: 56-61
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.